This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher (TMO) Beats on Q2 Earnings, Ups '18 EPS View
by Zacks Equity Research
Thermo Fisher (TMO) is performing well on the back of a series of product launches along with major progress in precision medicine initiatives.
Thermo Fisher Scientific (TMO) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 4.56% and 2.75%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher (TMO) Beats on Q2 Earnings & Sales Estimates
by Urmimala Biswas
Thermo Fisher (TMO) has launched innovative new products in the key technology platforms and also registered strong growth in Asia-Pacific and emerging markets, including China.
Medical Product Earnings Lineup for Jul 25: TMO, BSX & More
by Zacks Equity Research
The Medical product market further gains momentum on the back of a recent two-year suspension of the controversial 2.3% Medical Device tax.
Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Thermo Fisher (TMO) continues with its impressive performance momentum across analytical instrument businesses witnessing escalating global demand.
Roper Technologies (ROP) to Divest Gatan Business for $925M
by Zacks Equity Research
Roper Technologies (ROP) agrees to divest its Pleasanton, CA-based Gatan business to Thermo Fisher Scientific (TMO), against roughly $925 million cash.
Thermo Fisher to Buy Gatan, Boost Electron Microscopy Suite
by Zacks Equity Research
Thermo Fisher (TMO) forges ahead with initiatives to strengthen foothold in the high-potential electron microscopy market.
Genomics Market Gains Momentum: 3 DNA Stocks in Focus
by Nabaparna Bhattacharya
Here we discuss about how Genomics creates opportunities in MedTech for investors who are keen on putting money in the healthcare space.
Top Research Reports for UnitedHealth, Walmart & AT&T
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), Walmart (WMT) and AT&T (T).
Pacific Biosciences to Gain From New Genome Sequencing Tools
by Zacks Equity Research
Pacific Biosciences' (PACB) new multiplexing kit to make genome sequencing faster and cost-effective.
Bio-Rad Banks on Solid Global Scenario, Competition Rife
by Zacks Equity Research
Bio-Rad (BIO) delivers robust performance, primarily in North America, China and the Asia-Pacific region.
LabCorp, Unilabs Tie Up to Expand in Companion Diagnostics
by Zacks Equity Research
LabCorp (LH) continues to strengthen hold in the diagnostics space through inorganic means.
LabCorp Extends Aetna Agreement, Expands Diagnostics Business
by Zacks Equity Research
The expanded agreement enables LabCorp (LH) to serve as a preferred national laboratory to almost all of Aetna's members starting Jan 1, 2019.
LabCorp Extends UnitedHealthcare Pact, Lifts Diagnostics Arm
by Zacks Equity Research
LabCorp (LH) and UnitedHealthcare stretch links to collaborate on a variety of value-based programs.
Thermo Fisher (TMO) Gains on Latest Buyouts Despite Cost Woes
by Zacks Equity Research
Successive product launches and a marked progress in precision medicine initiatives boost Thermo Fisher's (TMO) performance.
Top Analyst Reports for Microsoft, Facebook, Intel & Boeing
by Zacks Equity Research
Today's Research Daily features new research reports on 17 major stocks, including Microsoft (MSFT), Facebook (FB), Intel (INTC) and Boeing (BA).
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, '18 View Up
by Zacks Equity Research
Thermo Fisher's (TMO) performance in Q1 benefits from a series of product launches alongside a major progress in precision medicine initiatives.
Thermo Fisher (TMO) Beats on Q1 Earnings & Sales Estimates
by Zacks Equity Research
Thermo Fisher (TMO) has launched innovative new products in the key technology platforms.
Medical Product Stock Earnings Roster for Apr 25: LH & More
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.
What's in the Offing for Thermo Fisher (TMO) in Q1 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) benefits from its acquisition of FEI, consistently adding stimulus to its analytical instruments portfolio for over a year now.
Thermo Fisher Strong on Global Business Amid Forex Woes
by Zacks Equity Research
Thermo Fisher (TMO) witnesses solid growth globally. Foreign exchange headwinds remain.
LabCorp Forms Lab-Alliance With Kentucky-Based Health Firm
by Zacks Equity Research
The multi-year, comprehensive laboratory deal to help LabCorp (LH) provide high-quality, high-value and standardized laboratory diagnostics for Appalachian Regional Healthcare.
The Zacks Analyst Blog Highlights: Amgen, FedEx, Thermo Fisher, Sherwin-Williams and Ameriprise
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, FedEx, Thermo Fisher, Sherwin-Williams and Ameriprise
Top Stock Reports for Amgen, FedEx & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), FedEx (FDX) and Thermo Fisher (TMO).
Thermo Fisher Scientific Buys IntegenX, Widens HID Suite
by Zacks Equity Research
Thermo Fisher Scientific (TMO) forges ahead with initiatives to strengthen its hold in the high-potential human identification market.